Neuropilin-2: A new molecular target for antiangiogenic and antitumor strategies

Journal of the National Cancer Institute

Volumn 100, Issue 2, 2008, Pages 81-83

  Narazaki, Masashi ^b   Segarra, Marta ^a   Tosato, Giovanna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LIPOSOME; NEUROPILIN 1; NEUROPILIN 2; PLACENTAL GROWTH FACTOR; SEMAPHORIN 3A; SEMAPHORIN 3F; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN D; VASCULOTROPIN E; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; SEMAPHORIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC THERAPY; CANCER GROWTH; CANCER THERAPY; COLORECTAL CANCER; EDITORIAL; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; METABOLISM; MOUSE; NOTE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; NEUROPILIN-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SEMAPHORINS;

EID: 38449115632     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm305     Document Type: Editorial

References (31)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
4. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol. 2007;39(7-8):1349- 1357.
5. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin. 2007;57(2):112-125.
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-974.
7. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer. 2006;6(8):626-635.
8. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610- 2621.
9. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24-40.
10. Gray MJ, Van Buren G, Dallas NA, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008;100(2):109-120.
11. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med. 2002;12(1):13-19.
12. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res. 2006;312(5):584-593.
13. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol. 2002;515:33-48.
14. Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev. 2001;109(1):115-119.
15. Yuan L, Moyon D, Pardanaud L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development. 2002;129(20):4797-4806.
16. Gu C, Rodriguez ER, Reimert DV, et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell. 2003;5(1):45-57.
17. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development. 1999;126(21):4895-4902.
18. Takashima S, Kitakaze M, Asakura M, et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA. 2002;99(6):3657-3662.
19. Shen J, Samul R, Zimmer J, et al. Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization. Mol Med. 2004;10(1-6):12-18.
20. Pan Q, Chanthery Y, Liang WC, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 2007;11(1):53-67.
21. Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther. 2006;5(5):1099-1107.
22. Staton CA, Kumar I, Reed MW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J Pathol. 2007;212(3):237-248.
23. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem. 2002;85(2):357-368.
24. Shimizu M, Murakami Y, Suto F, Fujisawa H. Determination of cell adhesion sites of neuropilin-1. J Cell Biol. 2000;148(6):1283-1293.
25. Murga M, Fernandez-Capetillo O, Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood. 2005;105(5):1992-1999.
26. Baba T, Kariya M, Higuchi T, et al. Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol Oncol. 2007;105(3):703-711.
27. Bielenberg DR, Hida Y, Shimizu A, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest. 2004;114(9):1260-1271.
28. Narazaki M, Tosato G. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood. 2006;107(10):3892-3901.
29. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem. 2007;282(36):26294-26305.
30. Roche J, Drabkin H, Brambilla E. Neuropilin and its ligands in normal lung and cancer. Adv Exp Med Biol. 2002;515:103-114.
31. Potiron VA, Sharma G, Nasarre P, et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res. 2007;67(18):8708-8715.